In our previously published study, we showed that vMyx-TNF/PBMC and the combination of vMyx-hTNF/PBMC + ICIs showed efficacy both in an early intervention model (i.e., treatment intervention beginning at 3 days post-tumor inoculation) and in an established disease model (i.e., treatment intervention beginning at group average lung tumor luminescence of 5 × 105). The gene discussed is TNF; the disease is neoplasm.